diagnost tool
price close busi februari
largest clinic lab us
focus routin gene-bas esoter test
larg lab environ easi quest
appear best posit buy pt
written larg lab lh rest non-
special lab industri face major challeng beyond said
believ quest better posit labcorp quest share gainer relat
contract indic volum build week expect
drive point off-set headwind relat
reimburs think bar set appropri like recov
pay dividend yield maintain buy trim
estim pt use multipl adj ep
result adj ep y/i match our/street rev
y/i miss our/street revenue /req decreas
far due ar reserv adjust relat unexpect
increas coverag denial patient respons bill system
convers one region lab impact abil estim reimburs
rate believ ar reserv issu indic tighten
level precis around complex estim go forward
volum look pois grow volum grew vs organ
volum grew mark highest point year
 tack point growth point estim volum grew
organ volum model growth
acquisit complet acquisit ad point growth vs
growth sum acquisit cost
guid assum point growth includ point
alreadi announc believ hospit ceos/cfo still
unawar financi pressur pama hospit outreach lab
expect ramp consolid lab
guid model initi revenue guid y/i
line prior lower follow analyst day
came street midpoint guid adj ep greater
vs prior lower revenue estim
model rev trim adj ep
modestli
respect estim exclud announc yet could add anoth
point growth
bright spot in-network statu extend commerci
cover live us indic volum good start
expect volum growth build year primarili add new live
unitedhealthcar target billion opportun time
build revenu pharma custom newer clinic trial connect
program expect lower cost structur offset
expect reimburs impact see opportun
consolid immuno-assay provid opportun year
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
guid disappoint revenu ep growth look pois bounc back
back half expect revenu flat-to-down y/i vs prior
y/i street estim expect adj ep similar
prior expect headwind
face includ account reserv adjust increas denial patient
concess leak key driver weak guid includ
increment cost drive awar new access one less sell
day compar one sell day continu
hep vitamin challeng move busi
unit out-of-network busi lower-pr in-network basi
manag indic expect on-going reimburs challeng payor
seek clinic evid support coverag indic expect see
benefit hepc lap headwind vitamin test headwind
lap march result lower revenu estim y/i
trim adj ep estim quest indic
mark easier comp lighter normal thu model
pace revenu adj ep back-end load
remind tailwind remind investor tailwind remain
expand health plan access live anthem horizon georgia
 revenue growth/year invigor cost save
year regard compani long-term target earn growth outlook
exclud share buyback author look like good time buy
thu think adj ep could talli year quest also expect expand
footprint expand access directli consum end
locat safeway store
look back novemb analyst day quest novemb lower
four-year earn growth target compound-annual-growth-rate mid-to-high-singl digit
cite headwind reimburs pama
carryov test headwind hcvg vit wage inflat
highlight challeng year ahead view
cover compani also mention report
laboratori corpor america hold lh nyse hold
buy unchang target price februari
diagnost tool
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price februari
diagnost tool
canaccord genuiti estim compani report
buy unchang target price februari
diagnost tool
canaccord genuiti estim compani report
buy unchang target price februari
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin februari et
date time product februari et
price target use multipl adj ep estim assum view modest
earn growth project believ potenti faster top-lin growth accret capit
deploy would mark upsid ep estim
laboratori corpor america hold lh
price target lh appli multipl adj ep
risk achiev target price valuat
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
buy unchang target price februari
diagnost tool
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
